Biopharmx (BPMX) Trading Down 7.1%
Biopharmx Corp (NYSEAMERICAN:BPMX) dropped 7.1% on Friday . The company traded as low as $0.13 and last traded at $0.13. Approximately 15,808,400 shares were traded during mid-day trading, an increase of 91% from the average daily volume of 8,269,592 shares. The stock had previously closed at $0.14.
Separately, Maxim Group restated a “buy” rating and issued a $1.50 price objective on shares of Biopharmx in a report on Friday, December 8th.
The stock has a market capitalization of $14.93, a price-to-earnings ratio of -0.48 and a beta of 1.33.
In related news, Director Stephen Morlock acquired 330,000 shares of the stock in a transaction that occurred on Friday, November 24th. The shares were bought at an average price of $0.15 per share, for a total transaction of $49,500.00. The acquisition was disclosed in a filing with the Securities & Exchange Commission, which can be accessed through the SEC website. Also, major shareholder Vivo Capital Viii, Llc sold 296,394 shares of the stock in a transaction that occurred on Thursday, November 9th. The shares were sold at an average price of $0.20, for a total transaction of $59,278.80. The disclosure for this sale can be found here.
BioPharmX Corporation is a specialty pharmaceutical company. The Company is focused on utilizing its drug delivery technologies to develop and commercialize prescription and over-the-counter (OTC) products that address markets in women’s health and dermatology. Its portfolio of product candidates includes two clinical stage product candidates: BPX01, which is a topical antibiotic for the treatment of acne based on a formulation of minocycline, and BPX03, which is a molecular iodine (I2) tablet for the treatment of benign breast pain associated with fibrocystic breast condition (FBC) and cyclic mastalgia.
Receive News & Ratings for Biopharmx Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Biopharmx and related companies with MarketBeat.com's FREE daily email newsletter.